Newsroom / COVID-19

In some territories, which are listed in our website footer, our microsampling devices are supplied for therapeutic or IVD use as referenced in some of our content. Outside of those territories our devices are supplied for research use only (RUO).

COVID-19 Spurred Mitra Microsampling Innovation in Bioanalysis

by Neoteryx, on September 23,2021

COVID-19 Spurred Mitra Microsampling Innovation in Bioanalysis

September 2021 — According to a preprint article slated for publication in the next issue of the journal Bioanalysis, the COVID-19 pandemic led to a shift in the way blood …

Read Story

US Population May Have More COVID-19 Immunity Than Previously Thought

by Neoteryx, on June 24,2021

US Population May Have More COVID-19 Immunity Than Previously Thought

June 2021 — According to a research article published online in the June 22, 2021 issue of Science Translational Medicine, data from a sero-surveillance study analyzing blood samples gathered from participants …

Read Story

Quanterix Publishes Study Paper on High-Sensitivity SARS-CoV-2 Test

by Neoteryx, on April 22,2021

Quanterix Publishes Study Paper on High-Sensitivity SARS-CoV-2 Test

At the end of March 2021, Quanterix Corporation issued a press release announcing that its Simoa® technology had been used in a research study to detect the SARS-CoV-2 virus. According …

Read Story

New Zealand Scientists Publish Study of Antibodies That Neutralize COVID-19

by Neoteryx, on March 17,2021

New Zealand Scientists Publish Study of Antibodies That Neutralize COVID-19

AUCKLAND, NEW ZEALAND – March 2021 – New Zealand has proved to be one of the most successful nations in responding effectively to the coronavirus pandemic and controlling the spread …

Read Story

Neoteryx Provides Remote Blood Collection Kits for COVID-19 Research

by Neoteryx, on July 18,2020

Neoteryx Provides Remote Blood Collection Kits for COVID-19 Research

According to a July 15, 2020 announcement posted on NewsWise, Vysnova Partners Inc., Wake Forest Baptist Health, and several other health organizations have received a $54-million contract from the US …

Read Story
Prev All Posts Next

The latest product releases, company news and microsampling industry updates from Neoteryx.

search our newsroom

news reporter resources:

If you don’t find the information & assets you need via the buttons below, please contact us here: press@neoteryx.com

Fact Sheet & FAQs
Neoteryx Experts

Media Contacts
Media Assets
Scientific Research Publications

social media

subscribe to news

Fuel Your Innovative Approach to Science & Research. Subscribe to Our Microsampling Newsletter!

Get Our Newsletter

 

Get in Touch

 

Neoteryx, LLC

© Neoteryx 2021 | Privacy Policy | Sitemap
421 Amapola Ave
Torrance, CA 90501

This site is protected by reCAPTCHA and the Google Privacy
Policy and Terms of Service apply.

part-of-trajan-family-logo-white-text

 

Get To Know Us

Follow Us

Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC. 

hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.  

Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.